Whole-genome sequencing classifies T-ALL subtypes more accurately, highlighting the importance of genomic alterations.
Whole-genome and whole-transcriptome sequencing enable biologically and clinically meaningful T-ALL subtype classification with greater precision than immunophenotype-based approaches. The genomic landscape of T-ALL is heavily influenced by noncoding alterations, posing a challenge for clinical applications, as their detection often requires whole-genome sequencing. Studies have identified genomic subtypes and genetic alterations that improve the accuracy of patient outcome prediction.
No takes yet. Share an insight, caveat, or question.
Pölönen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: